-
Company Insights
Innovation and Patenting activity of Norwegian Air Shuttle ASA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Norwegian Air Shuttle ASA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6035 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6035 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Relapsing Multiple Sclerosis (RMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6035 in Relapsing Multiple Sclerosis (RMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6035 in Relapsing Multiple Sclerosis (RMS) Drug Details: RG-6035 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AutoSynVax in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AutoSynVax in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AutoSynVax in Non-Small Cell Lung Cancer Drug Details: AutoSynVax is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AutoSynVax in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AutoSynVax in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AutoSynVax in Breast Cancer Drug Details: AutoSynVax is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AutoSynVax in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AutoSynVax in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AutoSynVax in Cervical Cancer Drug Details: AutoSynVax is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ropidoxuridine in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropidoxuridine in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropidoxuridine in Sarcomas Drug Details: Ropidoxuridine is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brainshuttle (BS) CD20-Multiple Sclerosis in Multiple Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brainshuttle (BS) CD20-Multiple Sclerosis in Multiple Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brainshuttle (BS) CD20-Multiple Sclerosis in Multiple Sclerosis Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropidoxuridine in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ropidoxuridine in Pancreatic Cancer Drug Details: Ropidoxuridine is under development for the treatment of sarcoma,...
-
Product Insights
Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus (HPV) Associated Cancer - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus (HPV) Associated Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...